A Phase 2 interventional study of Sorafenib (BAY-43-9006) in Sarcoma, Soft Tissue, sponsored by Istituto Clinico Humanitas. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-09-02.
Sponsored by Istituto Clinico Humanitas · Phase 2, Interventional, and Treatment
The aim of this study (*) is to evaluate the progression free survival rate at 6 months, response rate, overall disease control rate, overall survival of BAY-43-9006 in soft tissue sarcoma patients.
(*) as per Protocol Amendment No. 1 of 16 April 2007 approved by local IEC on 24 July 2007
1,667 studies on the registry are indexed under Sarcoma; 393 are open to participants now.
This study's enrollment of 69 is above the median of 40 across 1,283 interventional studies indexed under Sarcoma.
Browse Sarcoma studies →Istituto Clinico Humanitas is the lead sponsor of 275 studies on the registry; 71 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
800 mg/die orally on a continuous basis
Progression free survival rate
Time frame: at 6 months after enrollment
Overall response rate, overall disease control rate, overall survival
Time frame: Tumor assessment, follow-up
This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituto Clinico Humanitas